<p>BETHESDA (Bethesda System for Reporting Thyroid Cytopathology) 3 cytology results of thyroid nodules are indeterminate, making it difficult to make a treatment decision. This study aimed to determine the predictive utility of preoperative hemogram parameters and the BRAF molecular test in predicting malignancy in patients with Bethesda 3 cytology. This study examined patients who received total thyroidectomy/lobectomy as a result of Bethesda 3 cytology. The study patients were categorized into two groups based on the nature of their thyroidectomy pathology, either malignant or benign. Group B refers to benign cases, while Group M refers to malignant cases. The age and gender of all patients included in the study were recorded. The Mean Platelet Volume (MPV), Neutrophil/lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), and Lymphocyte/Monocyte Ratio (LMR) were calculated and documented in their preoperative hemograms. Molecular testing for the BRAF gene was conducted on 21 patients in Group M. This study revealed no statistically significant difference between the two groups regarding preoperative mean platelet volume (MPV) values (<i>p</i> = 0.963). A negative, considerable,&#xa0;and statistically significant association was seen in Group M between the average tumor size and the mean LMR value in patients having FTC (R.p = -0.975–0.005). The mean LMR value of patients with tumor size ≤ 10&#xa0;mm in Group M was significantly higher than in Group B (<i>p</i> = 0.040). According to the results obtained in our study, LMR elevation in ≤ 10&#xa0;mm Bethesda 3 cytology may be of limited help to clinicians in making biopsy decisions in the presence of risk criteria specified in the ATA guideline. Since the positivity rate of the BRAFV600E molecular test was determined to be very low, it was concluded that the BRAF v600E molecular test study alone was not sufficient to predict malignancy and was not cost-effective.</p>